Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Erweiterte Suche bearbeiten
Filter bei nächster Suche beibehalten
topic_facet:"Recruitment Status: Not yet recruiting"
topic_facet:"Medical Condition: Treatment of HIV-1 infections"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Not+yet+recruiting%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Treatment+of+HIV-1+infections%22&join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=ritonavir&type0%5B%5D=AllFields&op0%5B%5D=OR
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Not+yet+recruiting%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Treatment+of+HIV-1+infections%22&join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=ritonavir&type0%5B%5D=AllFields&op0%5B%5D=OR
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Not+yet+recruiting%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Treatment+of+HIV-1+infections%22&join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=ritonavir&type0%5B%5D=AllFields&op0%5B%5D=OR
PubPharm (12)
1
A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus. : A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
2
A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus. : A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
3
A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus. : A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2020
Wird geladen...
4
A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus. : A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2020
Wird geladen...
5
A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus. : A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2020
Wird geladen...
6
A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus. : A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2020
Wird geladen...
7
A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus. : A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2013
Wird geladen...
8
A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus. : A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2013
Wird geladen...
9
A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus. : A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2012
Wird geladen...
10
A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus. : A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2012
Wird geladen...
1
2
Nächster »
[2]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: Recruitment Status: Not yet recruiting
Filter aufheben
Thema: Medical Condition: Treatment of HIV-1 infections
Medienart
12
Aufsätze
12
E-Artikel
12
E-Ressourcen
Zeitschriftentitel
12
WHO International Clinical Trials Registry Plat...
Thema
12
610
Medical Condition: Treatment of HIV-1 infections
Recruitment Status: Not yet recruiting
12
Study Type: Interventional
6
Phase: Phase 3
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
6
2020-
6
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
12
Englisch
Haven't found what you're looking for?
Wird geladen...